Exagen
XGN
38 hedge funds and large institutions have $21.4M invested in Exagen in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
17.16% less ownership
Funds ownership: 65.93% → 48.77% (-17%)
19% less funds holding
Funds holding: 47 → 38 (-9)
75% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 12
92% less capital invested
Capital invested by funds: $277M → $21.4M (-$256M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Advisors Capital Management
Ridgewood,
New Jersey
|
+$151K |
| 2 |
RI
RTW Investments
New York
|
+$132K |
| 3 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$114K |
| 4 |
SAM
Silvercrest Asset Management
New York
|
+$64.3K |
| 5 |
BCI
Brinker Capital Investments
Berwyn,
Pennsylvania
|
+$47.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HT
HighTower Trust
Houston,
Texas
|
-$231M |
| 2 |
PIM
Platinum Investment Management
Sydney Australia 2000,
Australia
|
-$273K |
| 3 |
Millennium Management
New York
|
-$168K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$156K |
| 5 |
CAC
Cowen and Company
New York
|
-$145K |
XGN Hedge Fund Activity: Q3 2022 in Review
38 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Exagen (XGN) for Q3 2022, worth a combined $21.4M — down 92% from $277M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of XGN and 3 opened new positions — a net loss of 9 holders — while 14 trimmed existing stakes and 12 added.
The largest buyer was Advisors Capital Management, adding an estimated $151K. The largest seller was HighTower Trust, exiting entirely with an estimated $231M sold.
- 38 institutional investors held Exagen (XGN) as of Q3 2022, down from 47 in Q2 2022.
- Funds reported $21.4M of Exagen stock for Q3 2022, down 92% quarter-over-quarter.
- 3 funds opened new Exagen positions in Q3 2022 and 12 closed out, a net change of -9 holders.
- The largest Exagen buyer in Q3 2022 was Advisors Capital Management, an estimated $151K added.
- The largest Exagen seller in Q3 2022 was HighTower Trust, an estimated $231M sold.
Based on aggregated 13F filings for Q3 2022.